Toronto, Ontario–(Newsfile Corp. – October 12, 2023) – NuGen Medical Devices Inc. (TSXV: NGMD) (“company” or “newgenThe company, a leading developer of needle-free devices for subcutaneous therapeutic delivery, has announced the appointment of Ian Heynen as the company's new Chief Executive Officer, effective November 1, 2023. did.
Mr. Heinen is known in the medical technology industry as a top executive with decades of experience leading technology-driven organizations in startups, turnarounds, and accelerated growth companies. Masu. Mr. Heynen has experience leading and managing the income statements of North American and international businesses with multi-location divisions and gross revenues of up to $600 million or more. He has superior medical technology commercial execution expertise in developing and executing compelling strategic plans that deliver bottom-line results by structuring and aligning organizations towards strategic growth goals.
Most notably, Mr. Heinen was integral to the launch and growth of the start-up company Sentinel Medical, which attracted multinational buyer Hologic. He held several positions at Hologic, culminating in the role of Acting President. With multi-location divisions in Europe, the Middle East, Africa, Canada, Latin America and Asia Pacific, he leads an international business with more than 1,000 key employees and generates more than $600 million in total revenue. .
Mr. Hanen holds a combined CMA-MBA program (graduate gold medalist) from Wilfrid Laurier University (Toronto, Ontario) and a Master of Applied Science in Chemical Engineering from the University of British Columbia (Vancouver, British Columbia). Masu. He also holds a Bachelor of Applied Science in Chemical Engineering from the University of Waterloo (Waterloo, Ontario).
Mr. Heinen lives with his wife in Toronto, Canada, and is the father of three children. He has been a trustee of Kingsway College since 2017.
”I saw a great opportunity at NuGen to rapidly grow the company globally. My experience and expertise are a perfect fit for the trajectory of NuGen and its management team. As a builder of medical technology companies with over 20 years of experience, I'm excited to make a difference and am enthusiastic about the opportunities ahead.'' commented Ian Heinen.
”On behalf of the Company and the Board of Directors, I would like to welcome Ian to his new role as CEO of NuGen.” commented Executive Chairman Tony Di Benedetto.Ian’s expertise and appointment come at the perfect time, building on the successful turnaround we achieved in 2023. NuGen has assembled key ingredients for success that Ian's industry expertise is a perfect fit.”
”The Board and I would also like to thank Richard Buzbuzian for his hard work as CEO. Looking to 2023/2024 and beyond, we are excited to work with Ian as we incorporate NuGen into the next great medical technology story.” Di Benedetto added.
Richard Bazboudjian will continue to serve as President and Director of NewGen and will continue to focus on capital markets, corporate finance and investor relations. Mr. Heinen will focus on the full commercialization of the company with sales and manufacturing capabilities to drive growth while effectively managing the bottom line.
About Newgen
NuGen is a specialty medical device company marketing and selling the next generation InsuJet™ needle-free injection system designed to improve the lives of millions of people with diabetes. InsuJet™ is approved for sale in 42 countries worldwide.
See below for more information.
Website: www.insujet.com and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/
For more information, please contact us below.
Tony Di Benedetto
Executive Committee Chairman
(416) 791-9399
tony@nugenmd.com
Richard Bazboujian
President and CEO
(647) 501-3290
richard@nugenmd.com
To arrange a media interview with NuGen, please contact us below.
morna gorman
(416) 553-1732
morna@nugenmd.com
Notice regarding forward-looking information:
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Any statements that include predictions, expectations, beliefs, plans, projections, objectives, assumptions, discussions of future events or performance (including, but not always, phrases such as “expects,” “does not expect,” “anticipates,” etc.) ), “anticipate” or “not anticipate”, “plan”, “budget”, “scheduled”, “forecast”, “estimate”, “believe”, or ” “intended” or variations of such words or phrases, or expressing a particular action, event or result, “may”, “likely”, “will” occur or be achieved. “may” or “will” may be forward-looking statements that are not statements of historical fact. These forward-looking statements are subject to various risks, uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is provided as of the date hereof, and we do not intend to update or revise such information to reflect new events or circumstances, except as required by law. We are not responsible.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/183626.
